We are live on ! Find out more
HRTX icon

Heron Therapeutics

164 hedge funds and large institutions have $274M invested in Heron Therapeutics in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,362% more call options, than puts

Call options by funds: $4.21M | Put options by funds: $171K

56% more capital invested

Capital invested by funds: $176M → $274M (+$98.7M)

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

6.34% more ownership

Funds ownership: 75.57%81.91% (+6.3%)

2% more funds holding

Funds holding: 161164 (+3)

9% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
164
Holders Change
+3
Holders Change %
+1.86%
% of All Funds
2.2%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
24
Increased
50
Reduced
46
Closed
18
Calls
$4.21M
Puts
$171K
Net Calls
+$4.04M
Net Calls Change
-$511K
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.26M +$725K +373,518 +57%
Northern Trust
27
Northern Trust
Illinois
$2.19M -$31.8K -16,362 -2%
Bank of America
28
Bank of America
North Carolina
$2.13M -$153K -78,749 -8%
MAM
29
Monaco Asset Management
Monaco
$2.11M -$491K -252,743 -21%
SCM
30
Stonepine Capital Management
Oregon
$1.75M +$187K +96,100 +14%
BCM
31
Bridgeway Capital Management
Texas
$1.54M +$776K +400,000 +133%
JP Morgan Chase
32
JP Morgan Chase
New York
$1.53M +$259K +133,679 +24%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$1.47M -$300K -154,700 -19%
CM
34
CM Management
Florida
$1.32M -$194K -100,000 -14%
RB
35
Richmond Brothers
Michigan
$1.2M -$189K -97,438 -15%
Citadel Advisors
36
Citadel Advisors
Florida
$1.1M +$973K +501,490 New
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.07M -$1.71K -880 -0.2%
NAM
38
Nexpoint Asset Management
Texas
$1.05M
TD Asset Management
39
TD Asset Management
Ontario, Canada
$868K +$766K +394,600 New
EI
40
EAM Investors
California
$768K +$677K +349,000 New
Bank of New York Mellon
41
Bank of New York Mellon
New York
$722K -$24K -12,368 -4%
JFG
42
Jefferies Financial Group
New York
$710K +$626K +322,600 New
N
43
Nuveen
North Carolina
$691K
QOP
44
Quinn Opportunity Partners
Virginia
$616K -$194K -100,000 -26%
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$603K -$6.6K -3,399 -1%
AR
46
Apeiron RIA
Texas
$578K
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$505K +$359K +185,047 +418%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$439K +$274K +141,070 +242%
AllianceBernstein
49
AllianceBernstein
Tennessee
$437K
Barclays
50
Barclays
United Kingdom
$402K -$114K -58,800 -24%

HRTX Hedge Fund Activity: Q1 2025 in Review

164 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2025, worth a combined $274M — up 56% from $176M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new HRTX positions and 18 closed out — a net gain of 6 holders — while 50 added to existing stakes and 46 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $5.74M. The largest seller was Morgan Stanley, cutting an estimated $1.67M.

  • 164 institutional investors held Heron Therapeutics (HRTX) as of Q1 2025, up from 161 in Q4 2024.
  • Funds reported $274M of Heron Therapeutics stock for Q1 2025, up 56% quarter-over-quarter.
  • 24 funds opened new Heron Therapeutics positions in Q1 2025 and 18 closed out, a net change of +6 holders.
  • The largest Heron Therapeutics buyer in Q1 2025 was T. Rowe Price Associates, an estimated $5.74M added.
  • The largest Heron Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.67M sold.

Based on aggregated 13F filings for Q1 2025.